We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Neogen (NEOG) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
In its upcoming report, Neogen (NEOG - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.13 per share, reflecting an increase of 8.3% compared to the same period last year. Revenues are forecasted to be $223.03 million, representing a year-over-year decrease of 2.5%.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Neogen metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Revenues- Animal Safety' should arrive at $68.77 million. The estimate points to a change of -3.2% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Food Safety' will reach $154.26 million. The estimate indicates a year-over-year change of -2.2%.
Analysts' assessment points toward 'Revenues- Food Safety- Indicator Testing, Culture Media & Other' reaching $78.53 million. The estimate indicates a change of -3.3% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenues- Animal Safety- Veterinary Instruments & Disposables' will likely reach $17.93 million. The estimate points to a change of -0.3% from the year-ago quarter.
Analysts expect 'Revenues- Animal Safety- Animal Care & Other' to come in at $10.15 million. The estimate suggests a change of +0.8% year over year.
According to the collective judgment of analysts, 'Revenues- Food Safety- Natural Toxins & Allergens' should come in at $19.62 million. The estimate indicates a change of -0.6% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Food Safety- Rodent Control, Insect Control & Disinfectants' will reach $10.72 million. The estimate indicates a change of +5.7% from the prior-year quarter.
Analysts forecast 'Revenues- Food Safety- Bacterial & General Sanitation' to reach $39.60 million. The estimate suggests a change of -2% year over year.
The consensus estimate for 'Revenues- Animal Safety- Rodent Control, Insect Control & Disinfectants' stands at $21.16 million. The estimate points to a change of -8.2% from the year-ago quarter.
Over the past month, shares of Neogen have returned -18.5% versus the Zacks S&P 500 composite's -7.7% change. Currently, NEOG carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to Neogen (NEOG) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
In its upcoming report, Neogen (NEOG - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.13 per share, reflecting an increase of 8.3% compared to the same period last year. Revenues are forecasted to be $223.03 million, representing a year-over-year decrease of 2.5%.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Neogen metrics that are commonly tracked and projected by analysts on Wall Street.
Based on the collective assessment of analysts, 'Revenues- Animal Safety' should arrive at $68.77 million. The estimate points to a change of -3.2% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Food Safety' will reach $154.26 million. The estimate indicates a year-over-year change of -2.2%.
Analysts' assessment points toward 'Revenues- Food Safety- Indicator Testing, Culture Media & Other' reaching $78.53 million. The estimate indicates a change of -3.3% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenues- Animal Safety- Veterinary Instruments & Disposables' will likely reach $17.93 million. The estimate points to a change of -0.3% from the year-ago quarter.
Analysts expect 'Revenues- Animal Safety- Animal Care & Other' to come in at $10.15 million. The estimate suggests a change of +0.8% year over year.
According to the collective judgment of analysts, 'Revenues- Food Safety- Natural Toxins & Allergens' should come in at $19.62 million. The estimate indicates a change of -0.6% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Food Safety- Rodent Control, Insect Control & Disinfectants' will reach $10.72 million. The estimate indicates a change of +5.7% from the prior-year quarter.
Analysts forecast 'Revenues- Food Safety- Bacterial & General Sanitation' to reach $39.60 million. The estimate suggests a change of -2% year over year.
The consensus estimate for 'Revenues- Animal Safety- Rodent Control, Insect Control & Disinfectants' stands at $21.16 million. The estimate points to a change of -8.2% from the year-ago quarter.
View all Key Company Metrics for Neogen here>>>
Over the past month, shares of Neogen have returned -18.5% versus the Zacks S&P 500 composite's -7.7% change. Currently, NEOG carries a Zacks Rank #3 (Hold), suggesting that its performance may align with the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>